[Acquired coagulopathies].
Acquired coagulopathies regularly result from underlying diseases such as liver failure or sepsis. Optimal treatment of these underlying diseases defines longterm prognosis. In a few coagulopathies, such as immunocoagulopathies, in a relevant portion of patients an underlying disease cannot be identified. Therapeutic modulation of haemostasis aiming at the prevention of fatal bleeding or thromboembolism is able to improve the prognosis of patients with acquired coagulopathies. Most often this is the result of individualized, lab-controlled treatments, which are difficult to study. Within the last years the role of therapeutic modulation of haemostasis to reduce mortality was successfully studied for the first time in the frame of randomized placebo-controlled phase III studies.
Riess
H
H
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Campus Virchow-Klinikum, Universitätsklinikum Charité, Berlin.
D000925:Anticoagulants / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000209:etiology*; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D005171:Factor X Deficiency / Q000188:drug therapy; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D017093:Liver Failure / Q000150:complications; D008833:Microcirculation; D011379:Prognosis; D018805:Sepsis / Q000150:complications; D012772:Shock, Septic / Q000150:complications
D000925:Anticoagulants